- Home
- RBNE vs IMNN Comparison
RBNE vs IMNN Comparison
Compare RBNE & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RBNE
- IMNN
- Stock Information
- Founded
- RBNE 2024
- IMNN 1982
- Country
- RBNE Cyprus
- IMNN United States
- Employees
- RBNE N/A
- IMNN N/A
- Industry
- RBNE Marine Transportation
- IMNN Biotechnology: Pharmaceutical Preparations
- Sector
- RBNE Consumer Discretionary
- IMNN Health Care
- Exchange
- RBNE Nasdaq
- IMNN Nasdaq
- Market Cap
- RBNE 15.8M
- IMNN 12.9M
- IPO Year
- RBNE N/A
- IMNN 1985
- Fundamental
- Price
- RBNE $1.19
- IMNN $4.39
- Analyst Decision
- RBNE
- IMNN Buy
- Analyst Count
- RBNE 0
- IMNN 2
- Target Price
- RBNE N/A
- IMNN $182.61
- AVG Volume (30 Days)
- RBNE 3.6M
- IMNN 79.1K
- Earning Date
- RBNE 11-21-2025
- IMNN 11-05-2025
- Dividend Yield
- RBNE N/A
- IMNN N/A
- EPS Growth
- RBNE N/A
- IMNN N/A
- EPS
- RBNE N/A
- IMNN N/A
- Revenue
- RBNE N/A
- IMNN N/A
- Revenue This Year
- RBNE N/A
- IMNN N/A
- Revenue Next Year
- RBNE N/A
- IMNN N/A
- P/E Ratio
- RBNE N/A
- IMNN N/A
- Revenue Growth
- RBNE N/A
- IMNN N/A
- 52 Week Low
- RBNE $1.13
- IMNN $4.33
- 52 Week High
- RBNE $20.57
- IMNN $41.22
- Technical
- Relative Strength Index (RSI)
- RBNE N/A
- IMNN 30.98
- Support Level
- RBNE N/A
- IMNN $4.44
- Resistance Level
- RBNE N/A
- IMNN $4.90
- Average True Range (ATR)
- RBNE 0.00
- IMNN 0.32
- MACD
- RBNE 0.00
- IMNN -0.04
- Stochastic Oscillator
- RBNE 0.00
- IMNN 2.09
About RBNE Robin Energy Ltd. Common Stock
Robin Energy Ltd operates a tanker vessel that engages in the transportation of refined petroleum products using its Handysize product tanker.
About IMNN Imunon Inc.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).